Despite advances in biotechnology, there are still more than 7,000 diseases today with no effective treatment. There also continue to be disparities in global health as treatments for many infectious diseases do not attract sufficient research funding and pharmaceutical attention. According to the World Health Organization, nearly 2 billion people – one-quarter of the world – have no access to essential medicines.
Artificial intelligence (AI) and “simulation” are two technologies that promise to redefine drug development and enhance our ability to respond to global health crises.
Breaking through the challenges posed by previously undruggable targets requires technology that moves beyond AI into the world of first-principles physics. When we don’t have the data for AI to design effective therapeutics, simulation can fill the void, creating new datasets by digitally modelling biopharma compounds and rapidly simulating their chemical interactions with molecular targets within the human body.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
